legal · Europe / UK
DEA Makes Its Final Case for Cannabis Rescheduling as Full Hearing Transcripts Published

🌿 Plant Truth Index
Factual Record
90+ Stigma Breaker · 70+ Plant Forward · 40+ Factual Record · below 40 Prohibition Echo
As Chief Administrative Law Judge Derek Julius weighs his recommendation on moving cannabis to Schedule III, the DEA’s own closing brief attacks nearly every witness who opposed it — bar […] The post DEA Makes Its Final Case for Cannabis Rescheduling as Full Hearing Transcripts Published appeared first on Business of Cannabis .
As Chief Administrative Law Judge Derek Julius weighs his recommendation on moving cannabis to Schedule III, the DEA’s own closing brief attacks nearly every witness who opposed it — bar one scientist inside its own ranks.
With the full 2,533-page hearing transcript now publicly available, alongside both sides’ final written arguments, we now have the clearest picture yet of the cases made by each party, and more importantly, which held legitimate weight likely to influence the final recommendation.
After the 11-day testimony closed on July 14, 2026, written closing arguments were submitted on August 17 and 18, with the full corrected transcripts published days later. These additions provide significantly more detail than we’ve yet been able to access. Below is our breakdown of the key new information from the publications.
The DEA’s post-hearing brief provided perhaps the strongest statements in support of the shifting cannabis from Schedule I to Schedule III of the Controlled Substances Act of the entire hearing.
Filed on August 17, the brief states that cannabis ‘can no longer remain in Schedule I’, citing the ten-month scientific review conducted by the Department of Health and Human Services and the Food and Drug Administration, which found cannabis has a currently accepted medical use for pain, chemotherapy-induced nausea and vomiting, and anorexia linked to medical conditions, as its key source.
It goes on to reference more than 30,000 practitioners currently authorised to recommend cannabis to over 6m patients across 43 US jurisdictions as evidence of that use. While it does not deny the abuse and dependence risks associated with cannabis, it argues that the drug’s dependence profile aligns more closely with Schedule III than Schedule I or II.
Beyond providing its own scientific evidence, the DEA’s final brief takes aim at the credibility or relevance of nearly every witness on the opposing benches.
Yale psychiatrist Deepak D’Souza’s testimony on pain management is dismissed as outside his ‘admitted expertise’ in psychiatry.
Humboldt County Sheriff William Honsal is faulted for lacking any meaningful connection to the states that called him, Nebraska, Idaho and Indiana. This criticism played out in the transcripts. Under cross-examination by government counsel David Maley, Honsal agreed that his jurisdiction, California’s Emerald Triangle, falls under no sheriff’s authority in Nebraska, Indiana or Idaho.
DUID Victim Voices founder Ed Wood is accused of violating witness sequestration rules and offering ‘irrelevant and speculative’ testimony, while workplace-testing witnesses Patrice Kelly and Mary Jo McGuire are said to rest on ‘hypothetical, future hurdles.’
Even Bertha Madras, a Harvard Medical School psychiatry professor called by Smart Approaches to Marijuana (SAM) to argue against rescheduling, is cited approvingly for testimony the DEA says supports accepted use for neuropathic pain and cancer-related appetite loss.
Notably, Luli Akinfiresoye, a pharmacologist in the DEA’s own Drug and Chemical Evaluation Section, subpoenaed by SAM, escaped the DEA’s criticism.
The opposition’s closing briefs, filed the same week , are narrower and more defensive, largely reprising positions from testimony rather than breaking new ground.
Under cross-examination, several of these positions weakened considerably. Finn, the most frequently cited pain physician in the opposition’s filings, confirmed in a handful of questions that he has recommended cannabis to his own patients in the past, and agreed that, unlike opioid users, cannabis users do not stop breathing from the drug alone.
Emergency physician Karen Randall’s slide deck, intended to illustrate paediatric harm, featured a photograph of a child using a bong that she admitted came from a Reddit forum: asked how she knew the child in the photograph was real, she said, ‘I guess with your line of questioning, I don’t.’
Wood’s claim that rescheduling could produce 6,000 additional annual traffic deaths, similarly cracked under scrutiny: ‘We can’t say that those 6,000 deaths were all due to marijuana,’ he acknowledged. ‘There’s no intent to say that.’
Ben is the editor of Business of Cannabis. Since 2021, he has researched, written, and published the vast majority of the outlet’s content, delivering agenda-setting journalism on regulation, business strategy, and policy across Europe.